Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer

被引：10

作者：

Veneziani, Ana C. ^{[1
]}

Scott, Clare ^{[2
,3
,4
,5
]}

Wakefield, Matthew J. ^{[2
]}

Tinker, Anna V. ^{[6
]}

Lheureux, Stephanie ^{[1
]}

机构：

[1] Princess Margaret Canc Ctr, Div Med Oncol & Haematol, 610 Univ Ave, Toronto, ON M5B 2M9, Canada

[2] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia

[3] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia

[4] Royal Womens Hosp, Parkville, Vic, Australia

[5] Peter MacCallum Canc Ctr, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[6] BC Canc Agcy, Med Oncol, Vancouver, BC, Canada

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷

关键词：

biomarkers; homologous recombination deficiency; ovarian cancer; PARP inhibitor; replication stress; BRCA2 REVERSION MUTATIONS; CIRCULATING TUMOR DNA; CELL-FREE DNA; HIGH-GRADE; HOMOLOGOUS-RECOMBINATION; OPEN-LABEL; MAINTENANCE TREATMENT; CLINICAL ASSAYS; DAMAGE RESPONSE; REPAIR;

D O I：

10.1177/17588359231157644

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance. Ongoing studies address this challenge and investigate potential therapeutic strategies to prevent, overcome, or re-sensitize tumor cells to PARPi. This review aims to summarize the mechanisms of resistance to PARPi, discuss emerging strategies to treat patients post-PARPi progression, and discuss potential biomarkers of resistance.

引用

页数：22

共 50 条

[1] Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
Veneziani, Ana C.
Scott, Clare
Wakefield, Matthew J.
Tinker, Anna V.
Lheureux, Stephanie
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[2] Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer
Nikki L. Burdett
Madelynne O. Willis
Ahwan Pandey
Sian Fereday
Anna DeFazio
David D. L. Bowtell
Elizabeth L. Christie
[J]. Scientific Reports, 13 (1)
[3] Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer
Burdett, Nikki L.
Willis, Madelynne O.
Pandey, Ahwan
Fereday, Sian
DeFazio, Anna
Bowtell, David D. L.
Christie, Elizabeth L.
[J]. SCIENTIFIC REPORTS, 2023, 13 (01):
[4] Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Daniel Martin Klotz
Pauline Wimberger
[J]. Archives of Gynecology and Obstetrics, 2020, 302 : 1087 - 1102
[5] Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz, Daniel Martin
Wimberger, Pauline
[J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2020, 302 (05) : 1087 - 1102
[6] Overcoming PARP inhibitor resistance in ovarian cancer
Pina, Pamela Soberanis
Lheureux, Stephanie
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (03) : 364 - 376
[7] Mechanisms of PARP inhibitor resistance in ovarian cancer
Kubalanza, Kari
Konecny, Gottfried E.
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 36 - 41
[8] PARP Inhibitor Treatment in Ovarian and Breast Cancer
不详
[J]. CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 7 - 50
[9] PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
D'Andrea, Alan
[J]. ONCOLOGIST, 2017, 22 : S1 - S1
[10] Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
Wakefield, Matthew John
Nesic, Ksenija
Kondrashova, Olga
Scott, Clare L.
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1872 (02):

← 1 2 3 4 5 →